Press Release

09 Nov 2026

Zoetis to showcase new monoclonal antibody therapies at London Vet Show 2026

Zoetis Stand: Q50
Zoetis to showcase new monoclonal antibody therapies at London Vet Show 2026
- New long-acting monoclonal antibody therapies for the alleviation of pain associated with osteoarthritis (OA) in dogs and cats take centre stage at Zoetis stand Q50. 
- Zoetis Learning Academy explores how science, diagnostics and clinical insight can help veterinary teams detect disease earlier and manage complex conditions more effectively.
Zoetis UK Ltd. will showcase at London Vet Show (LVS) how its focus on science and innovation is helping advance animal care – from next-generation therapies to diagnostic solutions that support chronic disease management. Visitors to the stand can learn more about Lenivia®, launched in September, and Portela®, the company’s latest long-acting monoclonal antibody therapy for the alleviation of pain associated with feline osteoarthritis, launching at LVS. Delegates can also explore how Zoetis’ medicines and diagnostics portfolio support veterinary teams with a more proactive approach to chronic care, from earlier detection and diagnosis through to treatment and monitoring.

These launches demonstrate Zoetis’ continued commitment to advancing veterinary monoclonal antibody therapies (mAbs) and improving quality of life for companion animals by reducing OA pain. At the stand, Zoetis presents its new long-acting monoclonal antibody therapies for the alleviation of pain associated with osteoarthritis (OA) in dogs (Lenivia) and cats (Portela). Lenivia and Portela offer effective alleviation from pain associated with OA for up to three months with a single injection, acting via its novel binding to nerve growth factor (NGF), a recognised mediator of pain and inflammation. These treatments offer veterinary surgeons an additional option for long-term pain management and the extended dosing interval may help simplify treatment schedules while supporting continuity of care. Zoetis will host a launch celebration at its stand from 4 p.m. on Thursday for the Lenivia and Portela launches.

The stand will also demonstrate Zoetis’ wider approach to supporting clinical decision-making, including dermatology treatments Apoquel®, Cytopoint®, and Apoquel® Chewable and tools to strengthen communication with pet owners.
Zoetis Diagnostics' comprehensive, cutting-edge portfolio of point-of-care analysers and rapid tests are also at the stand, delivering deeply informed medical insights to support fast, confident treatment decisions. Visitors will have the opportunity to sign up to hear more about the new Vetscan OmniMax chemistry analyser coming soon, and explore the full range of solutions including the Vetscan Hub, Vetscan Vue+, Vetscan Imagyst, Vetscan VS2, and Vetscan OptiCell – each designed to elevate patient care through meaningful innovation.


“As
the world’s leading animal health company, we are proud to bring veterinary professionals innovation and industry-leading insights at London Vet Show this year, both on stand and in the Zoetis Learning Academy Theatre,” said Tim Burgess, Interim General Manager, Zoetis UK. “The challenges clinicians face are changing, from chronic disease in ageing pets to the pressure on practices to make timely decisions. Our role is to apply science to those problems, develop solutions that are clinically meaningful, and make sure they fit the realities of everyday veterinary care. Our offering at London Vet Show demonstrates our strong foundation in science and purpose, and our commitment to innovation, customer partnership, and industry advancement.”

Zoetis Learning Academy
The Zoetis Learning Academy Theatre will bring the latest developments in veterinary science and innovation directly to the show floor. Across two days, expert speakers will explore advances in monoclonal antibody science, osteoarthritis, disease detection, haematology, dermatology and chronic disease care, translating emerging evidence into practical insight for clinicians.

The programme reflects the company’s focus on unmet needs that become more pressing as animals live longer. Sessions on renal disease will explore earlier detection and disease progression, alongside innovations in animal health including monoclonal antibody research, approaches to osteoarthritis and updates in haematological medicine. Lectures on dermatology delve deeper into the compliance and care giver burden, and the role of the veterinary nurse in chronic disease care.

The Zoetis Learning Academy programme for Thursday, November 19, and Friday, November 20, is as follows: 

Thursday

Session

Speaker

10:00-10:50

The Biologics Revolution: Navigating the Past, Present, and Future of Monoclonal Antibodies in Veterinary Medicine

Richard Goldstein, Global Chief Medical Officer & Head of Medical Affairs, Zoetis

11:00-11:50

Catching the Quiet Decline: A Practical Approach to Renal Disease Detection

Adam Gow, Zoetis Global Clinical Consultation Lead and Zoetis Global Clinical Consultation Service, Zoetis

12:00-12:50

Canine Chronic Kidney Disease – Rethinking the Approach

Rosanne Jepson, Professor of Small Animal Internal Medicine and Nephrology, Royal Veterinary College

13:00-13:50

Recent evidence in disease progression in canine chronic kidney disease

Myles McKenna, Global Director of Veterinary Operations: Internal Medicine, Zoetis

14:00-14:50

The Haematology Toolbox Upgrade: Investigating Anaemia Without the Algebra

Mellora Sharman, Zoetis Global Clinical Consultation Service - Internal Medicine Consultant, Zoetis

15:00-15:50

RUMA CA&E - Managing the most common clinical conditions presented while practising good antibiotic stewardship in the consult room.

Steve Howard, RUMA CA&E Chair, Chief Veterinary Advisor at PDSA, RUMA

Friday

Session

Speaker

9:00-9:50

Chronic Disease Care: The essential role of the Veterinary Nurse

Jennifer Grant, Head Nurse, Dermatology Referral Service

10:00-10:50

Compliance and Caregiver Burden: The impacts of therapy choice

Jill Maddison, Professor of General Practice - Royal Veterinary College

Zoe Belshaw, Veterinary Consultant Researcher - EviVet

11:00-11:50

Librela - A Clinical Update

Ruth Moxon, National Veterinary Manager Pain, Zoetis

12:00-12:50

Introducing Lenivia

Richard Goldstein, Global Chief Medical Officer & Head of Medical Affairs, Zoetis

13:00-13:50

Introducing Portela

Richard Goldstein, Global Chief Medical Officer & Head of Medical Affairs, Zoetis


Find Zoetis at London Vet Show stand Q50 or the Zoetis Learning Academy Theatre. For more information please visit:
London Vet Show 2026 | Zoetis    


About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

Media Contact:
Kurtis L'Estrange, kurtis.lestrange@zoetis.com


MM-52880, November 2026 


View all Press Release
Loading
Hero Image

Education Partners

royal veterinary college university of london logo    british veterinary association logo 

Sponsors

diamond
platinum


silver